FindTrial
Sign In

Litifilimab

DRUG5 trials

Sponsors

Biogen

Conditions

Chronic Cutaneous Lupus ErythematosusHealthy VolunteerLupus Erythematosus, SystemicSubacute Cutaneous Lupus ErythematosusSystemic Lupus Erythematosus (SLE)

Phase 1

A Study to Find Out How Litifilimab is Processed in the Body in Healthy Participants When Given Under the Skin in 3 Different Ways
CompletedNCT06741657
BiogenHealthy Volunteer
Start: 2025-01-02End: 2026-03-10Updated: 2026-05-26

Phase 2

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
Active, not recruitingNCT05531565
BiogenChronic Cutaneous Lupus Erythematosus, Subacute Cutaneous Lupus Erythematosus
Start: 2022-09-13End: 2027-12-14Target: 450Updated: 2026-09-17

Phase 3

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
Active, not recruitingNCT04895241
BiogenLupus Erythematosus, Systemic
Start: 2021-05-25End: 2027-03-16Updated: 2026-02-10
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
Active, not recruitingNCT04961567
BiogenLupus Erythematosus, Systemic
Start: 2021-07-16End: 2027-03-16Updated: 2026-01-29
An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
Enrolling by invitationNCT05352919
BiogenSystemic Lupus Erythematosus (SLE)
Start: 2022-06-10End: 2030-03-29Target: 864Updated: 2026-09-11

Related Papers

LP-184 Rationale and design of two phase 3, Randomized, double-blind, placebo-controlled studies of the efficacy and safety of litifilimab in adults with active systemic lupus erythematosus: TOPAZ-1 and TOPAZ-2
2023-07-01